TTA-A2

TTA-A2 is an inhibitor of the T-type voltage-gated calcium (Cav) channels (IC50s = 89, 92, and 98 nM for Cav3.1, Cav3.2, and Cav3.3, respectively, in patch-clamp assays at -80 mV).1 It is selective for these channels over Cav1.2, Cav2.1, Cav2.2, and Cav2.3 in patch-clamp assays (IC50s = >30 µM for all at -90 mV). TTA-A2 (100 and 200 nM) reduces the viability of spheroid A549 lung cancer cells.2 It decreases body weight gain and fat mass and increases lean muscle mass in mice fed a high-fat diet when administered at a dose of 10 mg/kg.3 TTA-A2 (3 mg/kg) inhibits amphetamine- or MK-801-induced locomotor activity in rats.4 It reduces mean pulmonary arterial pressure and right ventricle hypertrophy in a rat model of hypoxic pulmonary hypertension induced by chronic housing in a hypobaric chamber.5 TTA-A2 (10 mg/kg) decreases the mean time spent in active wake and rapid eye movement (REM) sleep and increases the mean time spent in delta sleep in wild-type but not Cacna1g-/- and Cacna1i-/- double knockout mice when administered one hour before the inactive phase.1WARNING This product is not for human or veterinary use.

A T-type calcium channel inhibitor

378.4

≥98%

Biochemicals/Ion Channel Modulation/Blockers

Formal_Name:4-cyclopropyl-N-[(1R)-1-[5-(2,2,2-trifluoroethoxy)-2-pyridinyl]ethyl]-benzeneacetamide

O=C(CC1=CC=C(C2CC2)C=C1)N[C@H](C)C3=CC=C(OCC(F)(F)F)C=N3

953778-63-7

≥ 4 years

DMSO: Soluble: =10 mg/ml Ethanol: Soluble: =10 mg/ml